文献速递糖尿病肥胖与代谢综合征

葡萄糖不耐受肥胖妊娠期母体二甲双胍干预对老龄小鼠子代体成分和代谢健康的性别特异性影响

Sex-specific effects of maternal metformin intervention during glucose-intolerant obese pregnancy on body composition and metabolic health in aged mouse offspring.
PubMed 文献 · Diabetologia · 2022-09-16

研究用C57BL/6J雌鼠建立孕前肥胖模型,妊娠期每日给予300 mg/kg盐酸二甲双胍,追踪雄性和雌性子代至12月龄。结果显示母体二甲双胍暴露以性别和年龄依赖方式增加子代代谢风险因素,提示妊娠期干预后需对两性子代随访至成年早期之后。

要点

  • 12月龄时雄性和雌性Ob-Met子代均较Con子代出现肥胖增加和肝脏脂质蓄积。
  • 雄性Ob-Met子代8周至12月龄未出现增生,提示脂肪组织扩张受限。
  • 雌性Ob子代相对受保护,但雌性Ob-Met子代出现脂肪组织炎症和高胰岛素血症。

核心结论

  • 母体二甲双胍治疗肥胖母鼠以性别和年龄依赖方式增加子代代谢风险因素,提示妊娠期干预后应对两性子代随访至成年早期之后。
  • 研究说明在处方通过胎盘的治疗药物时,需权衡对母婴的短期获益与对子代任何潜在长期代谢影响之间的复杂性。

研究设计与样本

  • C57BL/6J雌鼠断奶后喂对照饮食(Con)或致孕前肥胖的致肥饮食(Ob),相应饮食维持至妊娠和哺乳期。
  • 肥胖母鼠随机分为未治疗组或妊娠期每日接受300 mg/kg盐酸二甲双胍治疗组(Ob-Met)。
  • 雄性和雌性子代从1月龄至12月龄测量体重和体成分,12月龄时采集血清和组织检测脂肪细胞细胞结构、脂肪组织炎症、肝脏脂质蓄积和纤维化。

主要发现

  • 12月龄时雄性Ob和Ob-Met子代较Con子代肥胖增加、脂肪细胞肥大、促炎基因表达升高、高瘦素血症和肝脏脂质蓄积。
  • 雄性Ob-Met子代8周至12月龄未出现增生,提示脂肪组织扩张受限,导致免疫细胞浸润增加和异位脂质沉积。
  • 雌性Ob子代相对免受这些表型影响,但雌性Ob-Met子代较Con雌性子代肥胖增加、脂肪组织炎症、肝脏脂质蓄积、高瘦素血症和高胰岛素血症。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Metformin is increasingly used to treat gestational diabetes (GDM) and pregnancies complicated by pregestational type 2 diabetes or polycystic ovary syndrome but data regarding long-term offspring outcome are lacking in both human studies and animal models. Using a mouse model, this study investigated the effects of maternal metformin intervention during obese glucose-intolerant pregnancy on adiposity, hepatic steatosis and markers of metabolic health of male and female offspring up to the age of 12 months. METHODS: C57BL/6J female mice were weaned onto either a control diet (Con) or, to induce pre-conception obesity, an obesogenic diet (Ob). The respective diets were maintained throughout pregnancy and lactation. These obese dams were then randomised to the untreated group or to receive 300 mg/kg oral metformin hydrochloride treatment (Ob-Met) daily during pregnancy. In male and female offspring, body weights and body composition were measured from 1 month until 12 months of age, when serum and tissues were collected for investigation of adipocyte cellularity (histology), adipose tissue inflammation (histology and quantitative RT-PCR), and hepatic steatosis and fibrosis (histochemistry and modified Folch assay). RESULTS: At 12 months of age, male Ob and Ob-Met offspring showed increased adiposity, adipocyte hypertrophy, elevated expression of proinflammatory genes, hyperleptinaemia and hepatic lipid accumulation compared with Con offspring. Male Ob-Met offspring failed to show hyperplasia between 8 weeks and 12 months, indicative of restricted adipose tissue expansion, resulting in increased immune cell infiltration and ectopic lipid deposition. Female Ob offspring were relatively protected from these phenotypes but Ob-Met female offspring showed increased adiposity, adipose tissue inflammation, hepatic lipid accumulation, hyperleptinaemia and hyperinsulinaemia compared with Con female offspring. CONCLUSIONS/INTERPRETATION: Maternal metformin treatment of obese dams increased offspring metabolic risk factors in a sex- and age-dependent manner. These observations highlight the importance of following up offspring of both sexes beyond early adulthood after interventions during pregnancy. Our findings illustrate the complexity of balancing short-term benefits to mother and child vs any potential long-term metabolic effects on the offspring when prescribing therapeutic agents that cross the placenta.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Schoonejans JM, Blackmore HL, Ashmore TJ, et al. Sex-specific effects of maternal metformin intervention during glucose-intolerant obese pregnancy on body composition and metabolic health in aged mouse offspring. Diabetologia. 2022. PMID: 36112170. doi:10.1007/s00125-022-05789-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。